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Abstract: An ideal tissue-engineered bone graft should have both excellent pro-osteogenesis and
pro-angiogenesis properties to rapidly realize the bone regeneration in vivo. To meet this goal, in
this work a porcine bone scaffold was successfully used as a Trojan horse to store growth factors
produced by mesenchymal stem cells (MSCs). This new scaffold showed a time-dependent release
of bioactive growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF), in vitro. The biological effect of the growth factors-adsorbed scaffold on the
in vitro commitment of MSCs into osteogenic and endothelial cell phenotypes has been evaluated.
In addition, we have investigated the activity of growth factor-impregnated granules in the repair of
critical-size defects in rat calvaria by means of histological, immunohistochemical, and molecular
biology analyses. Based on the results of our work bone tissue formation and markers for bone
and vascularization were significantly increased by the growth factor-enriched bone granules after
implantation. This suggests that the controlled release of active growth factors from porcine bone
granules can enhance and promote bone regeneration.
Keywords: bone scaffold; mesenchymal stem cells; angiogenic growth factors; delivery system;
bone regeneration
1. Introduction
Bone healing is a tightly regulated process that involves different cell types. During the first hours
after a trauma, there is the formation of a hematoma and an acute inflammatory response. Leukocytes
derived from blood and bone marrow leukocytes express pro-inflammatory cytokines and start the
healing process. Mesenchymal stem cells (MSCs) migrate from the surrounding tissue, then become
osteoprogenitor cells [1–3]. Tissue engineering offers a revolutionary approach to restore critical-sized
defects and, traditionally, this occurs by means of biomaterials, cells, and biologicals. Biomaterials
provide a three-dimensional (3D) substrate with specific engineered characteristics for cells to attach
and proliferate. In order to improve the migration and differentiation into the required tissue type
growth factors supply essential signaling cues for these kind of cells.
In this process angiogenesis, the formation of new blood vessels from pre-existing capillaries,
has a pivotal role since it provides the major contribution to inflammatory and regenerative events
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since it ensures blood supply to provide nutrition, oxygen, and osteoprogenitor cells through the
newly-formed blood vessels [4–8]. Moreover, several authors have previously indicated that there is
an interaction between angiogenesis and osteogenesis, in a way that the regulation of angiogenesis
plays a crucial role in bone remodeling through the wound healing process [9]. According to the
close relationship between angiogenesis, osteogenesis, and osseointegration, is needed when a tissue
engineering approach starts. The success of tissue engineering strategies is contingent on the ability of
blood vessels to form within the scaffolds and supply nutrients to the transplanted cells. The complicated
interplay of cells and cytokines at the interface of an implanted biomaterial must be deconstructed in
order to properly design an approach to harness inflammation and promote wound healing.
In order to improve or accelerate the bone healing process, new tools are offered to produce
scaffolds that act as carriers for growth factors with bone-related biological properties, such as bone
morphogenetic proteins (BMPs) and VEGF. The ability to enrich a scaffold with growth factors to
increase their release at the injured site could actively improve bone healing [10]. Notably, the healing
properties of bone rely on the recruitment of cells involved in the regeneration process, such as
progenitor cells, and in neovascularization at the injury site [11].
In the vast panorama of bone substitutes, porcine-derived scaffolds are showing great results in
terms of human bone regeneration, as confirmed by the positive results of clinical trials published by
several studies. Felice et al. [12–14], Covani et al. [15,16], Barone et al. [17–21], Calvo Guirado [22],
Crespi [23], and Scarano [24]; have demonstrated that the use of bone substitutes usually offers better
biomechanical performances than the spontaneously-healed bone in the same period. In all cases, an
increased bone density, often due to a significant increase in the trabecular number, seems to guarantee
an improved strength of the defect, a starting point favorable to the success of the next implant.
In light of such consideration, in the present work, we have investigated the biological basis
supporting this evidence, starting from the hypothesis that a porcine-derived bone scaffold could act
as a Trojan horse to entrap growth factors released by mesenchymal stem cells (MSCs) migrated to the
injured site to start the regeneration process. To perform this aim, we have seeded MSC on porcine
bone substitutes in vitro and then, after revoking the cells, evaluated the ability of the scaffolds to
release the growth factor entrapped and how this could direct the biological behavior of subsequently
re-seeded MSC. The effect on osteogenic and angiogenetic commitment on MSCs has been performed
in vitro. Then, these properties were evaluated in critical-sized calvaria defects in rats.
2. Results
2.1. Experimental Design
Porcine-derived bone granules were loaded with MSCs, in particular those isolated from human
dental pulp. It is well documented that these cells display multi-differentiation potential, with the
ability to give rise to osteoblasts, adipocytes, and chondrocytes. In addition, MSCs isolated from dental
pulp are capable of long-term cultivation without effect on their viability, phenotype, or genotype [25].
MSCs were in vitro cultured as a monolayer in cDMEM up to passage 1. At confluence, the cells
were harvested by trypsin treatment and seeded onto porcine HA-based scaffolds at a density of
1 × 106 cells/cm2 (Figure 1a). The cells were cultured for 7 days in cDMEM, changing the medium
twice a week. After this culturing time, cells were detached by trypsin treatment (Figure 1b), and the
decellularized scaffolds were air-dried overnight in a sterile biosafety cabinet. Then, new MSCs were
seeded on the same scaffolds at a density of 1 × 106 cells/cm2 and cultured for 14 days in cDMEM
(Figure 1c). Cells were cultured up to 14 days in order to evaluate their commitment ability in rats.
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Figure 1. Diagram of the experimental design. (a) Seeding of MSCs onto native porcine-derived bone 
granules; (b) decellularization of the seeded bone granules by trypsin treatment; and (c) seeding of 
the decellularized bone granules with other MSCs. 
After one week of culture, cells were able to colonize all of the scaffold surface, as evidenced by 
the staining against nuclei (Figure 2b, in blue). Figure 2a shows how native bone granules before 
seeding appear. No cells are present on the surface. Briefly: panel 2a is material that was never 
exposed to MSCs; panel 2b is the first exposure to MSCs and 2c and 2d are the second exposure to 
MSCs. After detaching cells with trypsin, the scaffolds were re-seeded with MSCs. The cells were 
found to adhere to the decellularized scaffold, as revealed by nuclei staining performed at 7 and 
after 14 days of culture (Figure 2c,d, in red). This experimental procedure was developed to evaluate 
the ability of the growth factors, secreted by the MSCs previously seeded onto bone granules, to be 
retained by the scaffold and to influence the osteogenic and vasculogenic commitment of stem cells. 
The MTT assay was additionally performed for assessing the residual cell viability in the 
decellularized bone granules. As shown in Figure 2e, the optical density (O.D.) value recorded for 
decellularized bone granules, granules enriched with MSC, granules after cell detachments, and 
granules re-seeded with MSC have been reported. Tests have been performed at 3, 7, and 14 days.  
As Figure 1e shows the decellularization process is able to eliminate all cells present since no O.D. 
value is detectable.  
 
Figure 1. Diagram of the experimental design. (a) S eding of MSCs onto native porcine-derived bone
granules; (b) decell l ri ti f t s e bone granules by trypsin treatment; and (c) seeding of the
decellularized bone granules with other MSCs.
After one week of culture, cells were able to colonize all of the scaffold surface, as evidenced
by the staining against nuclei (Figure 2b, in blue). Figure 2a shows how native bone granules before
seeding appear. o cells are present on the surface. Briefly: panel 2a is material that was never exposed
to MSCs; panel 2b is the first exposure to MSCs and 2c and 2d are the second exposure to MSCs.
After detaching cells with trypsin, the scaffolds were re-seeded with MSCs. The cells were found to
adhere to the decellularized scaffold, as revealed by nuclei staining performed at 7 and after 14 days
of culture (Figure 2c,d, in red). This experimental procedure was developed to evaluate the ability
of the growth factors, secreted by the MSCs previously seeded onto bone granules, to be retained by
the scaffold and to influence the osteogenic and vasculogenic commitment of stem cells. The MTT
assay was additionally performed for assessing the residual cell viability in the decellularized bone
granules. As shown in Figure 2e, the optical density (O.D.) value recorded for decellularized bone
granules, granules enriched with MSC, granules after cell detachments, and granules re-seeded with
MSC have been reported. Tests have been performed at 3, 7, and 14 days. As Figure 1e shows the
decellularization process is able to eliminate all cells present since no O.D. value is detectable.
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Figure 2. (a) Nuclear staining (in blue) of native bone granules; (b) Nuclear staining (in blue) of MSCs 
seeded onto bone granules after 7 days; (c) Staining of nuclei (in red) of MSCs seeded onto bone 
granules after decellularization and cultured for 7 (c) and 14 days (d); (e) MTT assay on bone 
granules alones (scaffolds); before seeding of MSC; after decellularization by trypsin treatment and 
after the second round of seeding. Tests have been performed at 3 days of culture (black bars); 7 days 
of culture (white bars); and 14 days of culture (grey bars). The graph represents the mean ± SD of 
three different experiments. Statistically significant differences are indicated as ** p < 0.01 compared 
with native bone granules. 
2.2. In Vitro Release of Growth Factors 
In order to obtain valuable information on the efficiency of the delivery system for the release of 
growth factors, an in vitro growth factors release test has been performed. This kind of study is, 
indeed, a prerequisite to achieve correct predictions to design and test the in vivo activity of 
controlled delivery forms. Figure 3 shows the amount of growth factors released from the 
impregnated bone granules after cell trypsinization compared to native bone granules in 
physiological solution plotted versus time. In this work, we have quantified two growth factors that 
are fundamental for the in vitro commitment of stem cells into an osteo-endothelial phenotype, that 
is basic fibroblast growth factor (bFGF) and VEGF. Analyzing their profiles, we observed a slight 
release of both the growth factors after 6 h of incubation in the physiological solution. The 
progressive increase of the release rate of bFGF and VEGF started after 6 h and reached a significant 
level after three days. 
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Figure 2. (a) Nuclear staining (in blue) of native bone granules; (b) Nuclear staining (in blue) of MSCs
seeded onto bone granules after 7 days; (c) Staining of nuclei (in red) of MSCs seeded onto bone
granules after decellularization and cultured for 7 (c) and 14 days (d); (e) MTT assay on bone granules
alones (scaffolds); before seeding of MSC; after decellularization by trypsin treatment and after the
second round of seeding. Tests have been performed at 3 days of culture (black bars); 7 days of culture
(white bars); and 14 days of culture (grey bars). The graph represents the mean ± SD of three different
experiments. Statistically significant differences are indicated as ** p < 0.01 compared with native
bone granules.
2.2. In Vitro Release of Growth Factors
In order to obtain valuable information on the efficiency of the deliver system for the rel ase
of growth factors, an in vitro growth facto s releas test has been performed. This kind of study is,
ind ed, rerequisite to achiev correct predictions to design and test the in vivo acti ity of controlled
delivery forms. Figure 3 hows the amount of growth factors released rom the impregnated bone
granules after cell trypsinization compared to native bone granul s in physiological solution plotted
ver us time. In this work, we have quantified wo growth factors that are fundamental for the in vitro
commitment of stem cells into an osteo-endothelial phenotype, that is basic fibroblast gr wth factor
(bFGF) and VEGF. Analyzing their profiles, we observed a slight release of both the growth factors
after 6 h of incubation in e physiological solution. The progressive increase of the release rate of
bFGF and VEGF started aft r 6 h and reached a significant level after three days.
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Figure 3. Quantification of growth factor release in physiological solution. (a) bFGF release, 
expressed as ng of growth factor versus mL of physiological solution plotted versus time, from 
impregnated bone granules (black line) and native bone granules (grey line); and (b) VEGF release, 
expressed as ng of growth factor versus mL of physiological solution plotted versus time, from 
impregnated bone granules (black line) and native bone granules (grey line). The graph represents 
the mean ± SD of three different experiments. Statistically significant differences are indicated as  
* p < 0.05 and compared with the growth factor release from native bone granules. 
2.3. In Vitro Effect of Growth Factors Adsorbed onto Bone Granules 
At this point, we proceeded with seeding MSCs onto the decellularized bone scaffolds obtained 
in the previous step; MSCs loaded onto native bone granules were used as the control. As reported 
in Figure 4a,b, the cells acquired an endothelial phenotype after two weeks of culture, as 
demonstrated by the immunofluorescence staining for CD31, a marker for mature endothelial cells. 
The positivity for the marker is evident for both the scaffolds, confirming the intrinsic ability of 
porcine bone granules to improve endothelial cell commitment. Nevertheless, a higher number of 
endothelial cells would be displayed if the granules were previously seeded with MSCs. The 
acquisition of a differentiated phenotype confirmed the good bioactivity of the endothelial growth 
factors secreted by MSCs. In addition, the ability of the scaffold to support osteogenic commitment 
has been verified by means of histological stainings. In particular, extracellular calcium deposits 
were evaluated trough von Kossa (Figure 4c,d) and Alizarin Red S (Figure 4e,f) stainings. In both 
cases, a positive reaction occurred, thus confirming the ability of the porcine bone granules to 
support osteogenic differentiation of stem cells. Additionally, in this case, the presence of growth 
factors on the scaffolds strongly improved the formation of a bone-like extracellular matrix. 
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t t is oi t, e rocee e it seeding SCs onto the decellularized bone scaffolds obtained
in the revio s ste ; S s loa e onto native bone granules were used as the control. As reported in
Figure 4a,b, the cells acquired an endothelial phenotype after two weeks of culture, as demonstrated
by the immunofluorescence staining for CD31, a marker for mature endothelial cells. The positivity
for the marker is evident for both the scaffolds, confirming the intrinsic ability of porcine bone
granules to improve endothelial cell commitment. Nevertheless, a higher number of endothelial
cells would be displayed if the granules were previously seeded with MSCs. The acquisition of
a differentiated phenotype confirmed the good bioactivity of the endothelial growth factors secreted
by MSCs. In addition, the ability of the scaffold to support osteogenic commitment has been verified
by means of histological stainings. In particular, extracellular calcium deposits were evaluated trough
von Kossa (Figure 4c,d) and Alizarin Red S (Figure 4e,f) stainings. In both cases, a positive reaction
occurred, thus confirming the ability of the porcine bone granules to support osteogenic differentiation
of stem cells. Additionally, in this case, the presence of growth factors on the scaffolds strongly
improved the formation of a bone-like extracellular matrix.
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Figure 4. Endothelial and osteogenic differentiation of MSCs seeded onto native bone granules  
(left column) or onto bone granules after decellularization (right column) after 14 days of culture. 
(a,b) Fluorescence images of cells expressing the endothelial cell marker CD31 (in green); nuclei are 
stained in blue; (c,d) von Kossa staining (10× magnification). Calcium deposits are visualized in 
black; (e,f) Alizarin Red S staining (10× magnification). Extracellular calcium-rich deposits are stained 
in purple. 
2.4. In Vivo Activity of Growth Factors Adsorbed onto Bone Granules 
The bone regeneration activity of the porcine bone scaffolds embedded with growth factors, 
such as bFGF and VEGF, was assessed in a rat calvarial defect model. We established the influence of 
growth factors on new bone formation (NBF), by comparing growth factor-adsorbed bone granules 
with native bone granules. Figure 5 shows that no inflammatory reaction around or inside the graft 
occurred in both conditions, but signs of tissue regeneration were evident. In particular, the grafts 
filled with native bone granules alone revealed the predominance of an extracellular matrix mainly 
consisting of collagen fibers (Figure 5a,c, blue arrows). On the contrary, the grafts filled with growth 
factor-embedded bone granules showed the prevalence of NBF (Figure 5b,d, yellow arrows) and 
more vessels (Figure 5b,d, white arrows). 
The quantity of NBF evaluated by histomorphometric analysis (Table 1) shows evidence of the 
higher value of new bone formation that is present in the site treated with the graft obtained after 
decellularization.  
Immunofluorescence analysis of calvarial grafts revealed the presence of collagen type III 
(Figure 6a,b, red fibers), and positivity for von Willebrand Factor (vWF, Figure 6c,d, in green) and 
for the VEGF receptor FLK-1 (Figure 6c,d, in green). A more detailed quantitative analysis of cells 
positive for endothelial markers, such as vWF and FLK-1, has been performed (Figure 6g). As it is 
well evidenced, a significantly high number of endothelial cells are present in the defects treated 
with bone granules after the decellularization process. 
Figure 4. Endothelial and osteogenic differentiation of MSCs seeded onto native bone granules
(left column) or onto bone granules after decellularization (right column) after 14 days of culture.
(a,b) Fluorescence images of cells expressing the endothelial cell marker CD31 (in green); nuclei are
stained in blue; (c,d) von Kossa staining (10× magnification). Calcium deposits are visualized in
black; (e,f) Alizarin Red S staining (10× magnification). Extracellular calcium-rich deposits are stained
in purple.
2.4. In Vivo Activity of Growth Factors Adsorbed onto Bone Granules
The bone regeneration activity of the porcine bone scaffolds embedded with growth factors, such
as bFGF and VEGF, was assessed in a rat calvarial defect model. We established the influence of
growth factors on new bone formation (NBF), by comparing growth factor-adsorbed bone granules
with native bone granules. Figure 5 shows that no inflammatory reaction around or inside the graft
occurred in both conditions, but signs of tissue regeneration were evident. In particular, the grafts
filled with native bone granules alone revealed the predominance of an extracellular matrix mainly
consisting of collagen fibers (Figure 5a,c, blue arrows). On the contrary, the grafts filled with growth
factor-embedded bone granules showed the prevalence of NBF (Figure 5b,d, yellow arrows) and more
vessels (Figure 5b,d, white arrows).
The quantity of NBF evaluated by histomorphometric analysis (Table 1) shows evidence of
the higher value of new bone formation that is present in the site treated with the graft obtained
after decellularization.
Immunofluorescence analysis of calvarial grafts revealed the presence of collagen type III
(Figure 6a,b, red fibers), and positivity for von Willebrand Factor (vWF, Figure 6c,d, in green) and
for the VEGF receptor FLK-1 (Figure 6c,d, in green). A more detailed quantitative analysis of cells
positive for endothelial markers, such as vWF and FLK-1, has been performed (Figure 6g). As it is well
evidenced, a significantly high number of endothelial cells are present in the defects treated with bone
granules after the decellularization process.
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Figure 5. Morphological analysis of bone grafts. Azan-Mallory staining (20× magnification) of (a,c) 
grafts filled with native bone granules alone; and (b,d) grafts filled with growth factors-embedded 
granules. Porcine bone granules (white asterisks) are surrounded by new bone (yellow arrows), 
some vessels (white arrows), and collagen fibers (blue arrows). (e) Histomorphometric analysis 
shows that the NBF area measured in bone grafts filled with bone granules enriched with growth 
factors is higher than the area of grafts filled with native granules alone. 
Table 1. Histomorphometric analysis. 
Sample Bone Granules after Decellularization Native Bone Granules 
1 146,937/μm2 134,765/μm2 
2 152,985/μm2 133,345/μm2 
3 135,982/μm2 135,102/μm2 
4 112,345/μm2 136,677/μm2 
5 142,367/μm2 1,339,875/μm2 
6 164,365/μm2 134,987/μm2 
7 132,535/μm2 123,667/μm2 
8 147,532/μm2 122,345/μm2 
9 161,223/μm2 133,556/μm2 
10 1,554,321/μm2 123,998/μm2 
11 159,988/μm2 101,654/μm2 
12 148,981/μm2 123,454/μm2 
Figure 5. Morphological analysis of bone grafts. Azan-Mallory staining (20×magnification) of (a,c) grafts
filled with native bone granules alone; and (b,d) grafts filled with gro th factors-embedded granules.
Porcine bone granules (white asterisks) are surrounded by new bone (yellow arrows), some vessels
(white arrows), and collagen fibers (blue arrows). (e) Histomorphometric analysis shows that the NBF
area measured in bone grafts filled with bone granules enriched with growth factors is higher than the
area of grafts filled with native granules alone.
i t r o etric analysis.
Sample Bone Granules after Decellularization (µm2) Native Bone Granules (µm2)
1 146,937 134,765
2 152,985 133,345
3 135,982 135,102
4 112,345 136,677
5 142,367 1,339,875
6 164,365 134,987
7 132,535 123,667
8 147,532 122,345
9 161,223 133,556
10 1,554,321 123,998
11 159,988 101,654
12 148,981 123,454
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Figure 6. Immunofluorescence stainings of cells expressing (a,b) collagen type III (red), a component 
of the extracellular matrix; (c,d) von Willebrand factor (green), an endothelial marker; and (e,f) FLK-1 
(green), one of the two VEGF receptor. Cell nuclei are stained blue. (g) Semiquantitative analyses of 
cells positive for vWF and FLK-1. Black bars indicate the number of cells present when native bone 
granules have been grafted and grey bars indicate the number of cells present when bone granules 
after decellularization were applied. Data represent the mean ± SD of cell number/histological 
section. ANOVA test: ** p < 0.01. 
Figure 6. Immunofluorescence stainings of cells expressing (a,b) collagen type III (red), a component
of the xtracell lar matrix; (c,d) vo Willebrand factor (green), an endothelial ma ker; nd (e,f) FLK-1
(green), one of the two VEGF receptor. Cell uclei a e stai ed blue. (g) Semiquantitative analyses of
cells positiv for vWF and FLK-1. Black bars indicate the number of cells presen wh n native bone
granules have been grafted and grey bars indicate the number of cells present he bone gra ules
after decellularization were applied. Data represent t e mean ± SD of cell number/hist logical section.
ANOVA test: ** p < 0.01.
A more detailed analysis of the cell population inside the bone grafts was performed using real-time
PCR. As shown in Figure 7, the presence of growth factors on the bone granules (black bars) considerably
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improved the osteogenic commitment, since runt-related transcription factor 2 (RUNX2), osteopontin,
osteonectin, osteocalcin, and collagen type I osteogenic markers were more strongly expressed than in
the native bone granules (white bars). Clearly, there was also a marked improvement in the expression
of the endothelial cell markers CD31, vWF, and VEGF in the growth factors-enriched samples.
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3. Discussion 
Drug delivery systems are devices that are developed from natural or synthetic materials to 
optimize the release of bioactive molecules [26]. There are usually some problems when a drug 
delivery system is used for bone regeneration: a shortage of vessel formation to maintain the 
long-term bone regeneration; and careful to keep a stable, controlled release of active growth factor. 
The safety and cost-effectiveness items related to the high supra-physiological doses of growth 
factor used without the optimization of the delivery systems induce a severe limitation on the 
translation to clinical use of this facing issue. 
The perfect device on tissue regeneration is the extracellular matrix (ECM) that plays a 
naturally fundamental role in coordinating and entrapping growth factor activity in vivo. Indeed, 
ECM, with its fiber network, is a highly dynamic microenvironment, able to provide mechanical 
cues and to control a multitude of cellular processes. ECM is the scaffold for migrating cells, thanks 
to its cell-binding sites for adhesion receptors, such as integrins, whose signaling regulates a number 
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3. Discussion
Drug delivery systems are devices that are developed from natural or synthetic materials to optimize
the release of bioactive molecules [26]. There are usually some problems when a drug delivery system is
used for bone regeneration: a shortage of vessel formation to maintain the long-term bone regeneration;
and careful to keep a stable, controlled release of active growth factor. The safety and cost-effectiveness
items related to the high supra-physiological doses of growth factor used without the optimization of
the delivery systems induce a severe limitation on the translation to clinical use of this facing issue.
The perfect device on tissue regeneration is the extracellular matrix (ECM) that plays a naturally
fundamental role in coordinating and entrapping growth factor activity in vivo. Indeed, ECM, with its
fiber network, is a highly dynamic microenvironment, able to provide mechanical cues and to control
a multitude of cellular processes. ECM is the scaffold for migrating cells, thanks to its cell-binding sites
for adhesion receptors, such as integrins, whose signaling regulates a number of cellular processes,
i.e., proliferation and differentiation. Moreover, ECM is an excellent reservoir for growth factors, since
many growth factors have the ability to bind specific sites within the ECM such as BMP-2, VEGF-A,
FGF; and PDGF-BB. Once attached to the ECM, growth factors are released depending on their
binding-affinity and the action of proteases. Therefore, the ECM, concerning its components, releases
these signaling molecules at different kinetics and from various locations, which allows an extremely
tight spatiotemporal regulation of cell fate within the wound microenvironment. Throughout the
different phases of the bone regeneration process, the multitude of growth factors that are released
bind specific sites within the provisional ECM with more or less affinity. Thus, growth factors will
first interact with the components of the matrix before finding their related cell-surface receptor.
When developing a growth factor delivery system, the primary aim is to deliver sustained small doses
of bioactive growth factors at a precise location. By analogy, the system goals to provide optimal
concentrations of growth factors within the target site and limit their systemic diffusion, closely
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resembling what the ECM does under physiological conditions. Towards this goal, both biomaterial
matrices and growth factors have been studied, taking inspiration from the natural interactions
between ECM and growth factors.
Secondly, while some growth factors have been demonstrated to be efficient in high doses in
multiple orthopedic and craniomaxillofacial applications, safety and cost-effectiveness issues have
driven research towards the development of better delivery systems allowing a reduction of the doses
and precise, controlled release.
In the present study, we aimed to elucidate whether bone substitutes adsorbed with growth
factors secreted by stem cells could represent a good natural delivery system able to stimulate
vascularization and promote bone repair. To answer this question, the first part of our work consisted
of the identification and quantification of growth factors adsorbed onto porcine bone substrates
previously seeded with MSCs derived from human dental pulp. We tested bFGF and VEGF because
they are considered potent activators for cells of mesenchymal origin, and fundamental for their
in vitro commitment into an osteo-endothelial phenotype [27,28]. The results of the growth factors
release assay demonstrated that the release of bFGF and VEGF was gradual up to three days; after
this time point, approximately 30% of the loaded growth factors were retained in the scaffold for
future release. It is well known that the natural process of bone regeneration involves the sequential
signaling of multiple cytokines and growth factors, which control each other and shape the regenerative
microenvironment. Therefore, instead of delivering a single type of signaling molecule at a high dose,
providing small doses of multiple key players simultaneously or sequentially could be more optimal
and safer. When delivering growth factors to augment bone regeneration, the first challenge is to know
which optimal concentrations of the right growth factors should be detected by the right cells at the
right time. On our natural system this equilibrium it seems to be respected. The presence of bFGF
and VEGF onto porcine bone granules could be explained as a consequence of the osteoinductive
properties of the scaffold, whcih is the ability of material to induce non-differentiated stem cells to
differentiate into bone-forming osteoblasts [29].
Another critical factor for successful bone regeneration is the mobilization of stem/progenitor
cells that have to proliferate and differentiate into bone cells. To evaluate whether the adsorbed growth
factors retained their bioactivity, we used these impregnated granules as substrates for the seeding
of other MSCs. The results of the histological analysis demonstrated that bFGF and VEGF positively
influenced the correct commitment of stem cells into an osteogenic and endothelial cell phenotype.
In the second part of our work, we investigated the ability of the porcine-derived bone granules
impregnated with growth factors to promote and facilitate bone tissue regeneration in critical-size
calvaria defects. Data collected after four weeks of in vivo experiments on rats showed that bFGF and
VEGF adsorbed onto bone granules improved collagen type III deposition, and the expression of vWF
and FLK-1 inside the scaffolds when compared to grafts filled with native bone granules. In addition,
the presence of these growth factors on the bone granules determined an elevated NBF together with
vessels formation, as revealed by histomorphological analyses. On the other hand, when pure bone
granules were engrafted on calvaria defects, the prevalence of an extracellular matrix mainly consisting
of collagen fibers was observed.
Furthermore, the biomimetically-coated surfaces increased the expression levels of RUNX2,
osteopontin, osteonectin, and osteocalcin after four weeks, and the concomitant expression of the
endothelial cell markers CD31, vWF, and VEGF. Therefore, matrix plus bFGF and VEGF improved the
effectiveness of osteoblast differentiation and matrix mineralization via angiogenesis. These results
together demonstrated the bone regeneration properties of the growth factors-embedded granules,
suggesting that the sustained release of bFGF and VEGF could continually stimulate angiogenesis and
bone healing.
We can assume that the enhanced orthotopic bone formation observed for the scaffolds enriched
with growth factors would benefit from the improved blood vessel network around, and within, the
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defective area. It is accepted that vascularization plays an important role in bone reconstruction since
it provides the necessary oxygen and nutrients to facilitate the neo-tissue growth [30].
Based on the results of our study, it can be supposed that after implantation into the bone defect
site, VEGF activated the proliferation of MSCs and endothelial cells in nearby vessels, leading to the
migration of cells out of their niches and to the vessel and the formation of growing sprouts. On the
other hand, VEGF is considered a key angiogenic factor that has the strongest and most significant
biological activity in enhancing blood vessel formation influencing MSC osteogenic commitment.
The first keyword is “controlled delivery”. Many previous investigations reported that initial burst
release followed by sustained release is better for promoting new bone formation. The second essential
item is “active release”. Although a lot of effort has been put into developing controlled delivery
systems for the use of VEGF in bone engineering applications, many of these systems continue
to have limitations associated with reduced biological activity after release. Based on the in vitro
characterizations and in vivo experiments, our findings demonstrated that porcine bone granules
could significantly enhance angiogenesis in vivo thanks to their ability to store growth factors in
a bioactive form and exerted a remarkable bone-healing capability in calvaria critical-size bone defect.
4. Materials and Methods
4.1. Biomaterials
Hydroxyapatite (HA)-based scaffolds made of cortico-cancellous porcine bone mix were supplied
in granules with dimensions of 250–1000 µm (Gen-Os, OsteoBiol by Tecnoss®, Torino, Italy).
4.2. MSCs Isolation
MSCs were isolated from human dental pulps extracted from healthy molar teeth of subjects, who
had given written consent.
Human dental pulps were extracted from healthy molar teeth, which had been extracted because
of mucosal inflammation (impacted teeth with pericoronitis) or for orthodontic reasons from adult
subjects aged 16 to 30. Each subject gave informed written consent for the use of their donated
dental pulps. The Ethical Committee of Padua Hospital approved the research protocol. Before
extraction, each subject was checked for systemic and oral infections or diseases. Only disease-free
subjects were selected for pulp collection. Each subject was pretreated for one week with professional
dental hygiene. Before extraction, the dental crown was covered with a 0.3% chlorexidin gel (Forhans,
New York, NY, USA) for 2 min. After mechanical fracturing, dental pulp was obtained by means
of a dentinal excavator or a Gracey curette. The pulp was gently removed and immersed for 1 h at
37 ◦C in a digestive solution: 100 U/mL penicillin, 100 mg/mL streptomycin, 0.6 mL of 500 mg/mL
clarithromycin, 3 mg/mL type I collagenase, and 4 mg/mL dispase in 4 mL of 1 M PBS. Once digested,
the solution was filtered through 70 µm Falcon strainers (Becton and Dickinson, Franklin Lakes,
NJ, USA). Stem cell isolation was performed according to our previously-published protocol [25].
The isolated cells were cultured with Dulbecco’s Modified Eagle Medium (DMEM) (Lonza S.r.l.,
Milano, Italy) supplemented with 10% fetal bovine serum (FBS) (Bidachem S.p.A., Milano, Italy) and
1% penicillin/streptomycin (P/S) (EuroClone, Milan, Italy) to form complete DMEM (cDMEM).
4.3. Experimental Design
MSCs were in vitro cultured as a monolayer in cDMEM up to passage 1. At confluence, the cells
were harvested by trypsin treatment and seeded onto porcine HA-based scaffolds at a density of
1 × 106 cells/cm2 (Figure 1a). The cells were cultured 7 days in cDMEM, changing the medium
twice a week. After this culturing time, cells were detached by trypsin treatment (Figure 1b).
Briefly, cellularized scaffolds were placed in 0.1% (w/v) Trypsin with a combination of 1 mmol/L
ethylenediaminetetraacetic acid, 20 mg/mL RNase, and 200 mg/mL DNase (dissolved in PBS) at 37 ◦C
for 24 h. In the second step, samples were incubated in HBSS (137 mmol/L NaCl, 5.4 mmol/L KCl,
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0.5 mmol/L KH2PO4, 4.1 mmol/L NaHCO3, and 0.33 mmol/L Na2HPO4 without Ca, Mg, and phenol
red) at 4 ◦C for 72 h. The solution was changed every 12 h (six times). The decellularized scaffolds
were air-dried overnight in a sterile biosafety cabinet. Then, new MSCs were seeded on the same
scaffolds at a density of 1 × 106 cells/cm2 and cultured for 14 days in cDMEM (Figure 1c).
4.4. MTT Assay
To determine the presence of viable cells in bone samples after decellularization, the MTT-based
proliferation assay was performed as described in Gardin et al. [31]. Briefly, bone samples were incubated
for 3 h at 37 ◦C in 1 mL of 0.5 mg/mL MTT solution prepared in PBS. After removal of the MTT solution
by pipette, 0.5 mL of 10% DMSO in isopropanol was added to extract the formazan in the samples for
30 min at 37 ◦C. For each sample, O.D. values at 570 nm were recorded in duplicate on 200 µL aliquots
deposited in microwell plates using a multilabel plate reader (Victor 3, Perkin Elmer, Milano, Italy).
4.5. Quantitative Analysis of Growth Factor Release
Immediately after cell trypsinization, growth factors release from porcine bone granules
previously seeded with MSCs and native bone granules was evaluated in 2 mL of physiological
solution using human ELISA kits (Sigma-Aldrich, Saint Louis, MO, USA). The growth factor release
was evaluated at 1 h, 6, 12, 24 h, 3 and 7 days.
4.6. Von Kossa and Alizarin Red S Stainings
Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) in PBS for 10 min at room temperature.
For von Kossa staining, fixed samples were incubated with 5% silver nitrate solution under ultraviolet
light for 1 h. After washing with ddH2O, unreacted silver was removed with 5% sodium thiosulfate
for 5 min. Cells were washed with ddH2O, counterstained with nuclear fast red for 5 min, then
washed again in ddH2O. For Alizarin Red S staining, fixed samples were stained adding 40 mm freshly
Alizarin Red S Solution (pH 4.2) for 10 min at room temperature with gentle shaking, then cells were
washed with ddH2O. In both cases, cells were observed under an optical microscope.
4.7. In Vivo Experiments
The in vivo study described here was approved by the Institutional Animal Care and Use
Com-mittee of Padova University. In vivo rat calvarial defect models of bone regeneration using
HA scaffolds were prepared for calvarial implantation in 12 eight-week-old male Sprague-Dawley
albino rats. Two defects were prepared for each rat: native porcine bone granules and bone granules
impregnated with growth factors. All operations were performed under general anesthesia obtained
with intraperitoneal injection of ketamine hydrochloride (Ketaras, Yuhan Corp. Korea, 40 mg/kg) mixed
with xylazine (Rumpens Bayer Korea Ltd., Seoul, Korea, 10 mg/kg). All operations were performed as
described elsewhere [32]. Animals were quarantined for two weeks to check their general health status.
Surgical procedures were then carried out in the authorized Veterinary Hospital of Padova University.
All the animals were treated and handled per the “Recommendations for Handling Laboratory
Animals for Biomedical Research” compiled by the Committee on the Safe and Ethical Handling
Regulation for Laboratory Experiments at the University of Padova. The animals were housed
separately in thermostat-controlled cages (22 ◦C) with a 12 h day/night cycle, unrestrained and
with food available ad libitum. The animals were sacrificed four weeks after surgery under
formalin perfusion.
4.8. Histological Analysis
The calvarial bone was removed from the skull and fixed in 4% paraformaldehyde solution in PBS
overnight. The fixed bone grafts were decalcified and then dehydrated in a graded series of ethanol.
After a brief step in xylene (Sigma-Aldrich), all the samples were paraffin-embedded and cut into
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7 µm thick sections. The sections were placed onto polylysine slides. The bone graft sections were
deparaffinized in xylene and rehydrated in graded concentrations of ethanol and then stained with
Azan-Mallory staining. The sections were then rinsed, dehydrated in a graded series of ethanol and
xylene, and coverslipped.
4.9. Histomorphometric Analysis
Histomorphometric analysis was performed on three random sections of each sample using a light
microscope equipped with a computerized image analyzer system (Qwin, Leica Microsystem Imaging
Solution Ltd, Cambridge, UK). Five photographs were taken from each section using a 20×magnification.
Software provided the NBF area values, which were expressed as the mean ± SD.
4.10. Immunofluorescence Staining
The sections were incubated in 2% bovine serum albumin (BSA, Sigma-Aldrich) solution in PBS
for 30 min at room temperature. The sections were then incubated with the primary antibodies in
2% BSA solution in a humidified chamber overnight at 4 ◦C. The following primary antibodies were
used: mouse anti-CD31 antibody; rabbit monoclonal anti-collagen type III antibody; mouse polyclonal
anti-von Willebrand factor antibody; mouse monoclonal anti-FLK-1 antibody. Immunofluorescence
staining was performed with secondary antibodies anti-mouse IgG DyLight 488 labeled and anti-rabbit
IgG (H + L) rhodamine (TRITC)-conjugated in 2% BSA for 1 h at room temperature. Nuclear staining
was performed with 2 µg/mL Hoechst H33342 (Sigma-Aldrich) solution for 2 min. The sections were
coverslipped with a drop of mounting medium.
4.11. Real-Time PCR
Total RNA was isolated from each bone sample by using the RNeasy Mini Kit (Qiagen GmbH,
Hilden, Germany), including DNase digestion with the RNase-Free DNase Set (Qiagen). For the
first-strand cDNA synthesis, 500 ng of total RNA of each sample was reverse transcribed with
M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s protocol.
Rat primers were selected for each target gene with Primer 3 software (Whitehead Institute for Biomedical
Research, Cambridge, MA, USA). Real-time PCR was carried out using the designed primers at a
concentration of 300 nM and FastStart SYBR Green Master (Roche Diagnostics, Mannheim, Germany)
on a Rotor-Gene 3000 (Corbett Research, Sydney, Australia). Thermal cycling conditions were as
follows: 15 min denaturation at 95 ◦C; followed by 40 cycles of denaturation for 15 s at 95 ◦C; annealing
for 30 s at 60 ◦C, and elongation for 20 s at 72 ◦C. Values were normalized (2∆Ct) to the expression
of the Transferrin Receptor (TFRC) internal reference, whose abundance did not change under our
experimental conditions.
4.12. Statistical Analysis
One-way analysis of variance (ANOVA) was used to analyze the data. Repeatability was
calculated as the standard deviation of the difference between measurements. All experiments were
repeated three times. All tests were performed using the SPSS 16.0 software package (SPSS Inc.,
Chicago, IL, USA) (licensed to the University of Padova, Italy).
4.13. Semi-Quantitative Analysis of Cells
In order to analyze endothelial cells present in the healed tissues treated with native bone
granules and with decellularized granules, masked microscopic examinations were performed
on immunostained sections. Cells were identified by vWF and FLK-1 monoclonal antibody
immunostaining, as described. Briefly, two investigators analyzed in a masked fashion at least 3 slides
for each experiment by light microscopy using 20 as the initial magnification. Each slide contained
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three sections of specimen, and five fields of 322 µm2 each, were analyzed for each tissue section.
Experiments were performed at least three times and values were expressed as the mean ± SD.
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